Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENTO in Mandibular Osteoradionecrosis
NCT02368457Phase 4Completed
- Sponsor
- Vall d'Hebron University Hospital
- Start
- Feb 2016
- Primary completion
- Feb 2016
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pentoxifylline and tocopherol in osteoradionecrosis (ORN), sponsored by Vall d'Hebron University Hospital. Primary endpoint: Bone and/or Tissue Healing at 9 months. Started Feb 2016; status: completed.
02
Drugs
pentoxifyllinetocopherol
03
Conditions
osteoradionecrosis (ORN)
Beyond the preview
Go deeper on NCT02368457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368457.